Liver-targeted chemo may boost survival in bile duct cancer

NCT ID NCT07304388

Completed Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a liver-directed chemotherapy infusion (HAIC) to a standard drug combo (Gemox, lenvatinib, toripalimab) helps people with advanced bile duct cancer live longer without the disease getting worse. 96 patients took part. The goal was to see if the extra treatment improves 6-month progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine, oxaliplatin, lenvatinib, toripalimab
What this could lead to: If adding liver-directed chemo works, it could offer a new option to control advanced bile duct cancer and extend life.
What could go wrong: This is a small phase 2 trial, so results may not be definitive. Adding more chemo could increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRAHEPATIC CHOLANGIOCARCINOMA (ICC)

Contacts and locations

Locations

Cancer Center Sun Yat-sen University

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.